Haitian-born billionaire Herriot Tabuteau's Axsome begins Phase 3 ADHD trial in children
Billionaires Africa | 08.07.2026 16:03
Axsome Therapeutics, the New York biotech run by Haitian-born billionaire Herriot Tabuteau, has dosed the first patient in a late-stage trial testing its wakefulness drug solriamfetol in children with attention deficit hyperactivity disorder, pushing further into a market it entered by buying a drug others had given up on.
